Long-term follow-up from the phase 1/2a GDFATHER-01 trial reported deep and durable remissions when the GDF-15-neutralizing antibody visugromab was added to nivolumab in immunotherapy-resistant advanced solid tumors. The update focuses on outcomes in patients who had already demonstrated insufficient responses to PD-1-based strategies. The findings strengthen the rationale for moving beyond single-axis checkpoint modulation by targeting tumor-mediated resistance biology. It also keeps GDF-15 in the spotlight as a potential immunotherapy-combination partner for patients with established resistance.
Get the Daily Brief